CL2007003680A1 - Sales de isoglutamil-d-triptofano; proceso de preparacion de dichas sales; composicion farmaceutica que comprende a dichas sales; proceso de preparacion de la composicion farmaceutica; utiles para el tratamiento de psoriasis y dermatitis atopica. - Google Patents

Sales de isoglutamil-d-triptofano; proceso de preparacion de dichas sales; composicion farmaceutica que comprende a dichas sales; proceso de preparacion de la composicion farmaceutica; utiles para el tratamiento de psoriasis y dermatitis atopica.

Info

Publication number
CL2007003680A1
CL2007003680A1 CL200703680A CL2007003680A CL2007003680A1 CL 2007003680 A1 CL2007003680 A1 CL 2007003680A1 CL 200703680 A CL200703680 A CL 200703680A CL 2007003680 A CL2007003680 A CL 2007003680A CL 2007003680 A1 CL2007003680 A1 CL 2007003680A1
Authority
CL
Chile
Prior art keywords
salts
pharmaceutical composition
preparation
isoglutamil
triptofan
Prior art date
Application number
CL200703680A
Other languages
English (en)
Inventor
Tim N Zemba Blaise Leung-T Tam
Original Assignee
Apotex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003680(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotex Technologies Inc filed Critical Apotex Technologies Inc
Publication of CL2007003680A1 publication Critical patent/CL2007003680A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL200703680A 2006-12-19 2007-12-18 Sales de isoglutamil-d-triptofano; proceso de preparacion de dichas sales; composicion farmaceutica que comprende a dichas sales; proceso de preparacion de la composicion farmaceutica; utiles para el tratamiento de psoriasis y dermatitis atopica. CL2007003680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002571645A CA2571645A1 (en) 2006-12-19 2006-12-19 Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture

Publications (1)

Publication Number Publication Date
CL2007003680A1 true CL2007003680A1 (es) 2008-03-14

Family

ID=39535926

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703680A CL2007003680A1 (es) 2006-12-19 2007-12-18 Sales de isoglutamil-d-triptofano; proceso de preparacion de dichas sales; composicion farmaceutica que comprende a dichas sales; proceso de preparacion de la composicion farmaceutica; utiles para el tratamiento de psoriasis y dermatitis atopica.

Country Status (14)

Country Link
US (2) US8138221B2 (es)
EP (1) EP2121729A4 (es)
KR (1) KR20090108034A (es)
CN (2) CN103554004A (es)
AU (1) AU2007335212B2 (es)
CA (2) CA2571645A1 (es)
CL (1) CL2007003680A1 (es)
MX (1) MX2009006673A (es)
PE (2) PE20121642A1 (es)
RU (1) RU2536685C2 (es)
TW (1) TWI406872B (es)
UA (1) UA106580C2 (es)
UY (1) UY30798A1 (es)
WO (1) WO2008074128A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579119C (en) 2007-02-16 2013-03-05 Apotex Technologies Inc. Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
RU2634258C1 (ru) * 2016-11-08 2017-10-24 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Наполнитель для капсульного ингалятора
RU2703991C1 (ru) * 2019-02-12 2019-10-23 Акционерное общество "Медико-биологический научно-производственный комплекс "Цитомед" (АО "МБНПК "Цитомед") Способ получения мононатриевой соли изоглутамил-триптофана

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3238118A1 (de) 1982-10-14 1984-04-19 Verla-Pharm, Arzneimittelfabrik Apotheker H.J. v. Ehrlich GmbH & Co KG, 8132 Tutzing Verfahren zur herstellung von komplexverbindungen aus aminodicarbonsaeuren, zweiwertigen metallionen und halogenidionen
AU566747B2 (en) * 1984-01-10 1987-10-29 Mitsui Chemicals, Inc. Method of separating l-tryptophan
US5902790A (en) 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
RU2107692C1 (ru) * 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
RU2107691C1 (ru) * 1995-03-02 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US6103699A (en) * 1996-06-07 2000-08-15 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
DE19540788A1 (de) * 1995-11-02 1997-05-07 Degussa Verwendung von wässrigen L-Tryptophan- und/oder L-Threonin-Salzlösungen
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
IL120923A0 (en) * 1997-05-27 1997-09-30 Amylum Nv A combined process for the production of lysine and its salts and of a further weak acid and a salt thereof
MX2009001351A (es) * 2006-08-04 2009-05-11 Manus Pharmaceuticals Canada L Compuestos bioactivos multifuncionales.
CA2569204A1 (en) * 2006-11-28 2008-05-28 Apotex Technologies Inc. Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan

Also Published As

Publication number Publication date
RU2536685C2 (ru) 2014-12-27
UA106580C2 (uk) 2014-09-25
EP2121729A1 (en) 2009-11-25
PE20081402A1 (es) 2008-11-16
TWI406872B (zh) 2013-09-01
TW200833708A (en) 2008-08-16
US20100056803A1 (en) 2010-03-04
PE20121642A1 (es) 2012-12-16
AU2007335212B2 (en) 2013-09-05
US20130072692A1 (en) 2013-03-21
AU2007335212A1 (en) 2008-06-26
RU2009127795A (ru) 2011-01-27
CA2673421A1 (en) 2008-06-26
US8735602B2 (en) 2014-05-27
CN101611050A (zh) 2009-12-23
MX2009006673A (es) 2009-11-02
WO2008074128A1 (en) 2008-06-26
US8138221B2 (en) 2012-03-20
KR20090108034A (ko) 2009-10-14
UY30798A1 (es) 2008-07-03
CN103554004A (zh) 2014-02-05
CA2571645A1 (en) 2008-06-19
CN101611050B (zh) 2013-10-30
EP2121729A4 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
CL2007003666A1 (es) Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras.
BRPI0812064A2 (pt) Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica
CL2007003423A1 (es) Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2008000224A1 (es) Composicion farmaceutica que comprende un compuesto derivado glucopiranosilo; y uso para el tratamiento de uno o mas trastornos neurodegenerativos.
CL2007003797A1 (es) Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
ES2968043T3 (es) Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que comprende la misma
CL2007003352A1 (es) Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
BRPI0815708A2 (pt) Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição.
BRPI0915084A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
ECSP099320A (es) Compuestos de tetrahidropirrolopiracina sustituida y su aplicación en medicamentos
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2015000462A1 (es) Composición fungicida y método para el control de las enfermedades de las plantas.
BRPI0816320A2 (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
CL2014001018A1 (es) Compuestos derivados de ciclohexilamina, agonistas ß2 y antagonistas muscarinicos m3; compuestos intermediarios; composicion farmaceutica; metodo para tratar una condicion fisiologica o enfermedad; y producto de combinacion que comprende al compuesto y a un corticosteroide o un inhiidor de pde4.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0816814A2 (pt) composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.
CL2008000981A1 (es) Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu
BRPI0915439A2 (pt) composição tópica para o tratamento de ceratose actínica
BRPI1013396A2 (pt) composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.